大博医疗12月15日大宗交易平台共发生1笔成交，合计成交量520.00万股，成交金额24440.00万元。成交 价格平均为47.00元，相对今日收盘价折价3.96%。 12月15日大博医疗大宗交易一览 （以上内容为自选股写手差分机完成，仅作为用户看盘参考，不能作为操作依据。） 风险提示：以上内容仅作为作者或者嘉宾的观点，不代表和讯的任何立场，不构成与和讯相关的任何投 资建议。在作出任何投资决定前，投资者应根据自身情况考虑投资产品相关的风险因素，并于需要时咨 询专业投资顾问意见。和讯竭力但不能证实上述内容的真实性、准确性和原创性，对此和讯不做任何保 证和承诺。 | 成交量(万 | 成交金额(万 | 成交价格 | 买方营业部 | 卖方营业部 | | --- | --- | --- | --- | --- | | 股) | 元) | (元) | | | | | | | 中信证券股份有限公司厦门分 | 中信证券股份有限公司厦门分 | | 520.00 | 24440.00 | 47.00 | 公司 公司 | | ...

《关于2024年股票期权激励计划预留授予登记完成的公告》 以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成 投资建议。 公司近日发布公告称，已完成2024年股票期权激励计划的预留授予登记工作。本次预留授予登记的股票 期权数量为62.04万份，涉及激励对象共89人，行权价格为23.39元/份。预留授权日为2025年9月17日， 授予登记完成日为2025年12月12日。股票期权代码为037947，简称大博JLC2。本次激励对象包括核心 管理人员及核心技术（业务）人员，不包括独立董事、监事等。公告中提及，公司层面的业绩考核目标 为2025年净利润不低于3.15亿元，2026年不低于4亿元。 最新公告列表 截至2025年12月12日收盘，大博医疗（002901）报收于46.75元，较前一交易日下跌2.34%，最新总市值 为193.55亿元。该股当日开盘47.84元，最高48.15元，最低46.75元，成交额达1.39亿元，换手率为 1.01%。 ...

证券代码：002901 证券简称：大博医疗 公告编号：2025-053 大博医疗科技股份有限公司 关于 2024 年股票期权激励计划预留授予登记完成的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚 假记载、误导性陈述或重大遗漏。 重要内容提示： 1、期权简称：大博 JLC2 2、期权代码：037947 3、预留授予登记数量：62.04 万份 4、预留授予登记人数：89 人 5、预留授予登记完成日：2025 年 12 月 12 日 根据大博医疗科技股份有限公司（以下简称"公司"）2024 年第二次临时股 东大会授权，公司于 2025 年 9 月 17 日召开第三届董事会第十九次会议和第三届 监事会第十八次会议，审议通过《关于向激励对象授予预留股票期权的议案》。 根据中国证券监督管理委员会《上市公司股权激励管理办法》、深圳证券交易所、 中国证券登记结算有限责任公司深圳分公司有关规则的规定，公司已完成 2024 年股票期权激励计划（以下简称"本激励计划"或"本次激励计划"或"《激励计划》"） 预留授予登记工作，现将相关事项公告如下： 一、本次激励计划已履行的相关审批程序 2、2024 年 9 ...

Core Viewpoint - The stock of Dabo Medical (002901) has shown a decline in price and mixed capital flow, with significant net outflows from retail investors, while institutional investors have shown some interest [1][3]. Group 1: Stock Performance - As of December 2, 2025, Dabo Medical's stock closed at 48.96 yuan, down 1.01%, with a turnover rate of 0.81% and a trading volume of 23,400 hands, resulting in a transaction amount of 116 million yuan [1]. - The net inflow of main funds on December 2 was 8.74 million yuan, accounting for 7.54% of the total transaction amount, while retail investors had a net outflow of 8.20 million yuan, representing 7.08% of the total [1]. Group 2: Financial Metrics - Dabo Medical's total market value is 20.27 billion yuan, with a net asset of 3.44 billion yuan and a net profit of 425 million yuan, ranking 12th, 43rd, and 17th respectively in the medical device industry [2]. - The company reported a year-on-year revenue increase of 22.69% for the first three quarters of 2025, with a total revenue of 1.876 billion yuan and a net profit increase of 77.03% to 425 million yuan [2]. - The gross profit margin stands at 71.23%, significantly higher than the industry average of 51.22%, indicating strong profitability [2]. Group 3: Institutional Ratings - In the last 90 days, one institution has issued a buy rating for Dabo Medical, indicating some level of confidence in the stock's potential [3].

Core Viewpoint - Dabo Medical (002901) shows a positive performance with a closing price of 49.46 yuan, up 2.68% as of December 1, 2025, indicating strong market interest and potential growth in the medical device sector [1]. Financial Performance - For the first three quarters of 2025, Dabo Medical reported a main revenue of 1.876 billion yuan, a year-on-year increase of 22.69% [2]. - The net profit attributable to shareholders reached 425 million yuan, reflecting a significant year-on-year growth of 77.03% [2]. - The third quarter alone saw a main revenue of 666 million yuan, up 17.82% year-on-year, with a net profit of 180 million yuan, also up 77.49% year-on-year [2]. - The company maintains a gross margin of 71.23%, which is significantly higher than the industry average of 51.22% [2]. Market Position - Dabo Medical's total market capitalization stands at 20.477 billion yuan, ranking 12th in the medical device industry [2]. - The company has a price-to-earnings ratio (P/E) of 36.17, which is lower than the industry average of 59.83, indicating a potentially undervalued stock [2]. - The return on equity (ROE) is reported at 12.83%, placing the company 7th in the industry rankings [2]. Capital Flow - On December 1, 2025, the net inflow of main funds was 6.1541 million yuan, accounting for 4.28% of the total transaction amount, indicating strong institutional interest [1]. - Over the past five days, there has been a mixed trend in capital flow, with retail investors showing a net outflow of 10.9273 million yuan on December 1, 2025 [1].

Core Points - The Shenzhen-Hong Kong Medical Index (983035) closed at 4554.17 points, up 0.2%, with a trading volume of 7.409 billion yuan and a turnover rate of 0.81% [1] - Among the index constituents, 38 stocks rose while 17 fell, with Yidu Technology leading the gainers at 3.5% and Mylab leading the decliners at 4.98% [1] Index Constituents Summary - The top ten constituents of the Shenzhen-Hong Kong Medical Index include: - Mindray Medical (sz300760) with a weight of 14.56% and a latest price of 201.62, down 1.17% [1] - Aier Eye Hospital (sz300015) with a weight of 11.62% and a latest price of 11.57, up 0.61% [1] - Lepu Medical (sz300003) with a weight of 4.85% and a latest price of 16.00, up 0.38% [1] - Aimeike (sz300896) with a weight of 4.80% and a latest price of 146.00, up 0.43% [1] - Yuyue Medical (sz002223) with a weight of 4.66% and a latest price of 36.25, up 1.54% [1] - Yingke Medical (sz300677) with a weight of 3.64% and a latest price of 43.48, up 0.95% [1] - Furuide (sz300049) with a weight of 3.59% and a latest price of 69.38, up 2.53% [1] - Meinian Health (sz002044) with a weight of 3.58% and a latest price of 5.27, down 1.50% [1] - Sinopharm (hk01099) with a weight of 3.35% and a latest price of 18.58, up 2.00% [1] - Ping An Good Doctor (hk01833) with a weight of 2.63% and a latest price of 13.53, up 1.22% [1] Capital Flow Analysis - The net outflow of main funds from the index constituents totaled 172 million yuan, while retail funds saw a net inflow of approximately 84.92 million yuan [3] - Notable capital flows include: - Sanbo Brain Science (301293) with a main fund net inflow of 26.77 million yuan [3] - Ruimait (301367) with a main fund net inflow of 16.21 million yuan [3] - Chutian Technology (300358) with a main fund net inflow of 11.20 million yuan [3] - The index constituents underwent an adjustment with one new stock added in the last ten days [3]

Core Viewpoint - The company, Dabo Medical, reassured investors that its operational status is normal despite recent stock price declines and shareholder reductions [1] Group 1 - Dabo Medical addressed investor concerns regarding the continuous decline in stock price and shareholder reductions [1] - The company confirmed that its operational situation remains stable and expressed gratitude for investor attention [1]

Core Insights - The 24th Chinese Orthopaedic Association (COA) conference showcased significant advancements in orthopedic technology, emphasizing the integration of robotics, navigation, imaging, and biomaterials under the theme "Digital Intelligence in Orthopedics" [2] - The conference attracted 20,188 registered participants and received 37,222 submissions, indicating a strong interest in orthopedic innovations [2] Group 1: Robotics and Navigation Systems - Surgical robots and navigation systems are expanding across various orthopedic fields, moving beyond joint surgeries to include spine, trauma, and sports medicine, focusing on precision and standardization [4] - Companies like Stryker, Tianzhihang, and others are presenting comprehensive orthopedic platforms that integrate imaging, navigation, and robotic arms, forming a closed-loop system for enhanced surgical outcomes [4] - The Trinity system by Tuo Dao Medical demonstrates a unified platform for rapid switching between surgical procedures, showcasing advancements in AI planning and real-time navigation [19] Group 2: Biomaterials and Bone Repair - The competition in bone repair and biomaterials is intensifying, with companies offering innovative solutions such as absorbable screws and 3D-printed bioceramics, focusing on osteogenic activity and infection resistance [4] - Smartbone and other manufacturers are introducing advanced materials that not only fill defects but also promote bone regeneration and integration [4] Group 3: Domestic Innovations - Domestic companies are accelerating the development of high-end joint prosthetics and key materials, with a focus on integrating materials, prosthetic design, and manufacturing processes [4] - The collaboration between local firms and international companies is shifting from product showcases to establishing standards and ecosystems, enhancing the overall orthopedic landscape [4] Group 4: Key Product Launches - Stryker highlighted its latest products, including the Mako robotic system, which integrates multiple surgical techniques for hip and knee replacements, enhancing precision and efficiency [5][7] - Rosenboht signed a strategic partnership with the Chinese University of Hong Kong to advance intelligent surgical technologies, aiming for more precise and minimally invasive orthopedic procedures [12][14] - The launch of the "Panshi Self-Pressing 3D Partition Bone Trabecular Biological Knee Prosthesis" by Jiashite Medical showcases advancements in mechanical stability and biological fixation [40][42] Group 5: Technological Integration - Companies are increasingly focusing on integrating AI and imaging technologies to enhance surgical precision and safety, as seen in the solutions presented by Meiya Optical and other firms [46][50] - The introduction of AR navigation systems by Linyan Medical represents a significant technological advancement, improving the visibility and accuracy of spinal surgeries [53][55] Group 6: Comprehensive Solutions - The conference highlighted the importance of comprehensive solutions that encompass preoperative planning, intraoperative guidance, and postoperative evaluation, as demonstrated by various exhibitors [4][60] - Companies like Weigao and others are showcasing integrated solutions that leverage digital technologies to enhance the entire orthopedic treatment process [100][102]

Core Insights - The Biotech Index (970038) closed at 2182.31 points, down 0.94%, with a trading volume of 13.462 billion yuan and a turnover rate of 1.08% [1] - Among the index constituents, 7 stocks rose while 42 stocks fell, with Xinlitai leading the gainers at 0.83% and Hualan Biological leading the decliners at 5.98% [1] Index Constituents Summary - The top ten constituents of the Biotech Index include: - Mindray Medical (sz300760) with a weight of 12.58%, latest price at 204.81, and a decline of 0.92% [1] - Changchun High-tech (sz000661) with a weight of 4.87%, latest price at 102.32, and a decline of 0.27% [1] - Shimeiao (sz002252) with a weight of 4.74%, latest price at 6.70, and a decline of 0.30% [1] - Kanglong Chemical (sz300759) with a weight of 4.55%, latest price at 29.16, and a decline of 1.22% [1] - Tigermed (sz300347) with a weight of 4.54%, latest price at 52.37, and a decline of 2.44% [1] - Shenzhen Technology (sz000021) with a weight of 4.16%, latest price at 23.90, and a decline of 1.77% [1] - Muyuan Foods (sz002714) with a weight of 3.62%, latest price at 48.45, and a decline of 0.31% [1] - Lepu Medical (sz300003) with a weight of 3.19%, latest price at 16.11, and a decline of 1.29% [1] - Aimeike (sz300896) with a weight of 3.16%, latest price at 155.51, and an increase of 0.58% [1] - Yuyue Medical (sz002223) with a weight of 3.07%, latest price at 35.28, and a decline of 0.20% [1] Capital Flow Analysis - The Biotech Index constituents experienced a net outflow of 1.382 billion yuan from major funds, while retail investors saw a net inflow of 1.358 billion yuan [1] - Notable capital flows include: - Aimeike (sz300896) had a net inflow of 26.5772 million yuan from major funds, but a net outflow from retail investors of 20.4422 million yuan [2] - Changchun High-tech (sz000661) saw a net inflow of 8.8418 million yuan from major funds, with a slight net inflow from retail investors of 186.25 thousand yuan [2] - Other stocks like Furuisi (sz300049) and Yuyue Medical (sz002223) also showed mixed capital flows with significant net outflows from retail investors [2]

大博医疗科技股份有限公司 证券代码：002901 证券简称：大博医疗 公告编号：2025-052 大博医疗科技股份有限公司（以下简称"公司"）第三届董事会已于 2025 年 10 月 27 日任期届满。鉴于公司新一届董事会换届工作尚在积极筹备中，为确 保公司董事会相关工作的连续性及稳定性，公司董事会的换届选举工作将适当延 期，公司董事会各专门委员会、高级管理人员的任期亦将相应顺延。 在新一届董事会换届选举完成前，公司第三届董事会成员、董事会各专门委 员会委员及高级管理人员将依照法律法规和《公司章程》等相关规定继续履行相 应的职责和义务。公司延期换届不会影响公司的正常生产经营，公司将积极推进 董事会换届工作，并按照相关规定及时履行信息披露义务。 特此公告。 大博医疗科技股份有限公司 关于董事会延期换届的提示性公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚 假记载、误导性陈述或重大遗漏。 董事会 2025 年 11 月 19 日 1 ...